KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Liabilities: 2009-2024

Historic Total Liabilities for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $455.0 million.

  • Acadia Pharmaceuticals' Total Liabilities rose 3.46% to $413.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $413.5 million, marking a year-over-year increase of 3.46%. This contributed to the annual value of $455.0 million for FY2024, which is 43.43% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Total Liabilities of $455.0 million as of FY2024, which was up 43.43% from $317.2 million recorded in FY2023.
  • Acadia Pharmaceuticals' Total Liabilities' 5-year high stood at $455.0 million during FY2024, with a 5-year trough of $155.6 million in FY2020.
  • Its 3-year average for Total Liabilities is $319.9 million, with a median of $317.2 million in 2023.
  • Data for Acadia Pharmaceuticals' Total Liabilities shows a peak YoY skyrocketed of 85.14% (in 2020) over the last 5 years.
  • Over the past 5 years, Acadia Pharmaceuticals' Total Liabilities (Yearly) stood at $155.6 million in 2020, then grew by 2.33% to $159.2 million in 2021, then rose by 17.69% to $187.4 million in 2022, then skyrocketed by 69.27% to $317.2 million in 2023, then skyrocketed by 43.43% to $455.0 million in 2024.